Using multiple databases, we performed gene expression analysis, prognostic analysis, variant analysis, immune analysis, and methylation analysis of the NSD family and identified that NSD3 was highly expressed in pancreatic cancer and associated with poor prognosis, which was validated in our pancreatic cancer cohort. Here, SLC17A5 is linked to familial pancreatic carcinoma.